Aclaris Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACRS research report →
Range $3 – $10
Price Chart
About the company
Aclaris Therapeutics, Inc. , a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services.
- CEO
- Neal S. Walker
- IPO
- 2015
- Employees
- 71
- HQ
- Wayne, PA, US
Get TickerSpark's AI analysis on ACRS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $545.63M
- P/E
- -6.03
- PEG
- -0.13
- P/S
- 86.73
- P/B
- 3.14
- EV/EBITDA
- -6.75
- Div Yield
- 0.00%
- Gross Margin
- 99.81%
- Op Margin
- -1413.97%
- Net Margin
- -1244.09%
- ROE
- -59.20%
- ROIC
- -47.16%
Latest fiscal year · YoY change
- Revenue
- $7.83M-58.2%
- Gross Profit
- $5.74M-64.0%
- Op Income
- $-76,375,000
- Net Income
- $-64,923,000+50.8%
- EPS
- $-0.53+69.0%
- OCF Growth
- -134.7%
- FCF Growth
- -133.8%
- 52W High
- $6.60
- 52W Low
- $2.34
- 50D MA
- $4.25
- 200D MA
- $4.54
- Beta
- 0.80
- RSI (14)
- 39
- Avg Volume
- 3.07M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Aclaris shifted ATI-2138 into a proof-of-concept atopic dermatitis study, while quarter-end cash came in at $161 million and management said near-term cash burn should fall after one-time cleanup costs roll off.· May 7, 2024
- ATI-2138 is now headed into a 15-patient, 12-week open-label Phase 2 study in moderate to severe atopic dermatitis.
- Management argued ATI-2138’s dual ITK/JAK3 mechanism could differentiate it from ritlecitinib and broader JAK inhibitors.
- Phase 1 data were described as showing linear PK and dose/time-dependent PD inhibition, with 50% to 90% inhibition at 5 to 40 mg BID.
- Cash, cash equivalents and marketable securities were $161 million at quarter-end versus $182 million at year-end, with no debt.
- Company said it is still reviewing strategic options and looking at business development for non-dilutive capital.
Aclaris did not report revenue or EPS on this call. It said quarter-end cash, cash equivalents and marketable securities were $161 million, down from $182 million at year-end, with 0 outstanding debt. Management said approximately $14 million of first-quarter cash expenditures were tied to nonrecurring items, including discontinued R&D programs, severance, and payments related to the Sun licensing upfront amount. For ATI-2138, the company moved the asset into a proof-of-concept Phase 2 study in moderate to severe atopic dermatitis; the study will be open label, 12 weeks, and enroll 15 patients. Management expects activities tied to discontinued programs and the reduction in force to be substantially completed by the second quarter of 2024, and said quarterly cash expenditures for the rest of the year should be significantly reduced versus Q1, excluding any business development transactions.
Neal Walker said the main strategic shift was to advance ATI-2138 into atopic dermatitis, which he framed as a Th2-driven disease where ITK inhibition could matter. He emphasized the company’s hypothesis that dual ITK/JAK3 inhibition could create additive or synergistic effects, and said the goal is to prove out the ITK contribution with biomarkers in the new study. His tone was upbeat on the mechanism and pragmatic on execution, stressing speed, capital efficiency, and the potential to use the data to decide on the next indication or study.
Kevin Balthaser said Aclaris ended the quarter with $161 million in cash, cash equivalents and marketable securities and no debt, versus $182 million at year-end. He attributed about $14 million of Q1 cash spending to one-time items tied to discontinued programs, severance from the December reduction in force, and Sun licensing-related payments. He said those cleanup activities should be mostly finished by Q2 2024 and that quarterly cash expenditures should be significantly lower for the remainder of the year, apart from any business development activity. He also noted the company is still evaluating business development opportunities as a source of non-dilutive capital.
Analysts focused on how ATI-2138 compares with ritlecitinib and upadacitinib, whether the dual ITK/JAK3 mechanism can create synergy, and why management chose a 10 mg BID dose and an open-label design. Management said the dose was selected based on preclinical exposure data and comparison to ritlecitinib, while the open-label study was chosen for speed, enrollment practicality, and cost efficiency. They also said the company is not giving timing guidance yet for top-line Phase 2a data, except that it should be within a year of the call, and confirmed they are funded to complete the proof-of-concept study.
The bull case from this call is that ATI-2138 has a differentiated mechanistic story and the company believes it can outperform more JAK-selective drugs in atopic dermatitis by adding ITK inhibition. Management pointed to Phase 1 PK/PD consistency, preclinical activity, and the ability to run a small, fast, capital-efficient proof-of-concept study with enough cash to get there.
The biggest risks are that this is still early, open-label, and small, so clinical differentiation in atopic dermatitis remains unproven. Management also acknowledged it has not yet provided timing guidance for data beyond saying it should arrive within a year, and it is still reviewing strategic options rather than committing to a long-term development path.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 71.7%
- Shares Outstanding
- 158.61M
- Float Shares
- 113.65M
of shares held by institutions
156 13F filers
Buy/sell ratio 1.09. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ra Capital Management, L.P. | 12.72M | ▲ 5.92M |
| Bml Capital Management, LLC | 10.96M | ▼ 1.02M |
| Blackrock, Inc. | 10.38M | ▲ 339.58K |
| Deep Track Capital, LP | 9.35M | 0 |
| Fmr LLC | 7.05M | ▲ 6.73M |
| Vivo Capital, LLC | 6.69M | 0 |
| Vanguard Group Inc | 6.50M | ▼ 13.38K |
| Vanguard Capital Management LLC | 5.86M | ▲ 46.75K |
| Frazier Life Sciences Management, L.P. | 4.93M | 0 |
| Rock Springs Capital Management LP | 4.33M | ▼ 142.12K |
| Adage Capital Partners Gp, L.L.C. | 4.07M | ▲ 200.00K |
| Decheng Capital LLC | 4.04M | 0 |
Held by 173 ETFs
Biggest fund positions in ACRS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 1, 26 | Kolbeck Roland Wilhelm | other | 36,375 |
| Aug 1, 26 | Kolbeck Roland Wilhelm | other | 36,375 |
| Aug 1, 26 | Kolbeck Roland Wilhelm | other | 12,385 |
| Jun 5, 26 | Mehra Anand | other | 11,580 |
| Jun 4, 26 | SCHIFF ANDREW N | other | 42,350 |
| Jun 4, 26 | Mehra Anand | other | 42,350 |
| Jun 5, 26 | SCHIFF ANDREW N | other | 11,580 |
| Jun 4, 26 | Mehra Anand | other | 10,987 |
| Jun 4, 26 | SCHIFF ANDREW N | other | 10,987 |
| Jun 5, 26 | Mehra Anand | other | 11,580 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ACRS coverage
Recent articles, reports, and earnings notes.

Rezera Inc. IPO: What Investors Need to Know
Rezera Inc. is expected to list on NASDAQ on 2026-11-12 under the symbol RZRA, with shares priced in a $11.00 to $13.00 range. The company is offering 16,666,667 shares in a clinical-stage biotech IPO built around oral NLRP3 inhibitors. The bull case is a large unmet need in PAD and a pipeline with strategic backers; the bear case is that Rezera has no revenue, no approved product, and a long clinical path ahead.

Should You Buy the Parabilis Medicines IPO? Here's the Setup
Parabilis Medicines (NASDAQ: PBLS) is expected to list on 2026-06-10, with shares priced at $17.00 to $19.00. The company is offering 25,000,000 shares and is targeting a $546,250,000 market cap. The bull case is a differentiated oncology platform; the bear case is a clinical-stage biotech with no disclosed commercial revenue.
Want a deeper read on ACRS?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Has Consensus Price Target of $10.67
defenseworld.net · Nov 19
This Aclaris Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
benzinga.com · Nov 17
Why is Aclaris Therapeutics Stock Trading Lower on Monday?
benzinga.com · Nov 16
Aclaris Therapeutics, Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
benzinga.com · Nov 16
Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)
globenewswire.com · Nov 16
Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)
globenewswire.com · Nov 16
Aclaris Therapeutics to Participate in the Jefferies Global Healthcare Conference
globenewswire.com · Nov 12
Aclaris Therapeutics (NASDAQ:ACRS) vs. Oncocyte (NASDAQ:IMDX) Financial Contrast
defenseworld.net · Nov 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.